Table 2 Descriptive data on antimicrobial susceptibility testing and Beta lactamase genes among isolates that tested positive for ESBL
ESBL Genes | ||||||||
|---|---|---|---|---|---|---|---|---|
blaCTX-M | blaSHV | blaTEM | blaOXA | |||||
Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | |
N = 12 | N = 142 | N = 12 | N = 142 | N = 66 | N = 88 | N = 106 | N = 48 | |
Chloramphenicol | ||||||||
Susceptible | 5 (42%) | 63 (44%) | 6 (50%) | 62 (44%) | 19 (29%) | 49 (56%) | 41 (39%) | 27 (56%) |
Non susceptible | 7 (58%) | 79 (56%) | 6 (50%) | 80 (56%) | 47 (71%) | 39 (44%) | 65 (61%) | 21 (44%) |
Ciprofloxacin | ||||||||
Susceptible | 4 (33%) | 71 (50%) | 6 (50%) | 69 (49%) | 36 (55%) | 39 (44%) | 61 (58%) | 14 (29%) |
Non susceptible | 8 (67%) | 71 (50%) | 6 (50%) | 73 (51%) | 30 (45%) | 49 (56%) | 45 (42%) | 34 (71%) |
Gentamicin | ||||||||
Susceptible | 2 (17%) | 17 (12%) | 1 (8%) | 18 (13%) | 4 (6%) | 15 (17%) | 14 (13%) | 5 (10%) |
Non susceptible | 10 (83%) | 125 (88%) | 11 (92%) | 124 (87%) | 62 (94%) | 73 (83%) | 92 (87%) | 43 (90%) |
Ceftriaxone | ||||||||
Susceptible | 1 (8%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (2%) | 0 (0%) | 1 (1%) | 0 (0%) |
Non susceptible | 11 (92%) | 142 (100%) | 12 (100%) | 141 (99%) | 65 (98%) | 88 (100%) | 105 (99%) | 48 (100%) |
Cefoxitin | ||||||||
Susceptible | 11 (92%) | 133 (94%) | 10 (83%) | 134 (94%) | 62 (94%) | 82 (93%) | 99 (93%) | 45 (94%) |
Non susceptible | 1 (8%) | 9 (6%) | 2 (17%) | 8 (6%) | 4 (6%) | 6 (7%) | 7 (7%) | 3 (6%) |
Amoxicillin/ clavulanate | ||||||||
Susceptible | 6 (50%) | 54 (38%) | 6 (50%) | 54 (38%) | 29 (44%) | 31 (35%) | 42 (40%) | 18 (38%) |
Non susceptible | 6 (50%) | 88 (62%) | 6 (50%) | 88 (62%) | 37 (56%) | 57 (65%) | 64 (60%) | 30 (62%) |
Aztreonam | ||||||||
Susceptible | 1 (8%) | 3 (2%) | 0 (0%) | 4 (3%) | 1 (2%) | 3 (3%) | 2 (2%) | 2 (4%) |
Non susceptible | 11 (92%) | 139 (98%) | 12 (100%) | 138 (97%) | 65 (98%) | 85 (97%) | 104 (98%) | 46 (96%) |
Ceftazidime | ||||||||
Susceptible | 2 (17%) | 6 (4%) | 1 (8%) | 7 (5%) | 4 (6%) | 4 (5%) | 7 (7%) | 1 (2%) |
Non susceptible | 10 (83%) | 136 (96%) | 11 (92%) | 135 (95%) | 62 (94%) | 84 (95%) | 99 (93%) | 47 (98%) |
Cefotaxime | ||||||||
Susceptible | 1 (8%) | 1 (1%) | 0 (0%) | 2 (1%) | 2 (3%) | 0 (0%) | 1 (1%) | 1 (2%) |
Non susceptible | 11 (92%) | 141 (99%) | 12 (100%) | 140 (99%) | 64 (97%) | 88 (100%) | 105 (99%) | 47 (98%) |
Azithromycin | ||||||||
Susceptible | 7 (58%) | 103 (73%) | 8 (67%) | 102 (72%) | 53 (80%) | 57 (65%) | 83 (78%) | 27 (56%) |
Non susceptible | 5 (42%) | 39 (27%) | 4 (33%) | 40 (28%) | 13 (20%) | 31 (35%) | 23 (22%) | 21 (44%) |
Imipenem | ||||||||
Susceptible | 11 (92%) | 139 (98%) | 12 (100%) | 138 (97%) | 64 (97%) | 86 (98%) | 103 (97%) | 47 (98%) |
Non susceptible | 1 (8%) | 3 (2%) | 0 (0%) | 4 (3%) | 2 (3%) | 2 (2%) | 3 (3%) | 1 (2%) |
Meropenem | ||||||||
Susceptible | 11 (92%) | 141 (99%) | 12 (100%) | 140 (99%) | 66 (100%) | 86 (98%) | 105 (99%) | 47 (98%) |
Non susceptible | 1 (8%) | 1 (1%) | 0 (0%) | 2 (1%) | 0 (0%) | 2 (2%) | 1 (1%) | 1 (2%) |